[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414079":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":38,"responsibleParty":54,"collaborators":56,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Retrospective Cohort",null,"Patients who have previously had radiotherapy and then have had their local residual\u002Frecurrent disease managed with salvage TORS at the Royal Marsden Hospital will be eligible for inclusion. They will be informed of the RECUT+ study by a member of their usual care team at RMH during their routine outpatient appointments for follow up of their H\\&N cancer.\n\nPotential participants will be asked to consent to provide blood\u002Fsaliva sample for germline DNA and for permission for their original tumour biopsy sample and their residual\u002Frecurrent resection to undergo DNA analysis. Where patients have returned to their referring institution and are no longer under active regular follow up at RMH, a research pack will be sent to the patient via post and email. This pack will contain the Cover Letter, the Participant Information Sheet and the Informed Consent Form. It will also contain a saliva collection tube, buccal swab, blood tubes and instructions for how to provide blood\u002Fsaliva samples.",[13],"Other: DNA Analysis",{"label":15,"type":10,"description":16,"interventionNames":17},"Prospective Cohort","Patients who have previously had radiotherapy and then are due to have their local residual\u002Frecurrent disease managed with salvage transoral robotic surgery at the Royal Marsden Hospital (RMH) will be approached prior to their salvage surgery at a routine outpatient appointment. They will be asked to consent to provide blood\u002Fsaliva sample for germline DNA pre and post operatively. They will also be asked for permission for their original tumour biopsy sample and their residual\u002Frecurrent resection to undergo DNA analysis",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DNA Analysis","Molecular analysis includes DNA analysis on the blood\u002Fsaliva and on the cancer specimens from the biopsies \\& subsequent resections",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Prof Vinidh Paleri","The Royal Marsden Hospital NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Vishak C Muraleedharan Shylaja, MBChB","CONTACT","442073528171","vishak.muraleedharanshylaja@rmh.nhs.uk",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Sarah Burton","020 8661 3567","sarah.burton@rmh.nhs.uk",[39],{"facility":40,"status":41,"city":42,"state":10,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The Royal Marsden Hospital","RECRUITING","London","SW3 6JJ","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-0.12574,51.50853,{"lat":50,"lon":49},[53],{"name":25,"role":31,"phone":10,"phoneExt":10,"email":10},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[57,60],{"name":58,"class":59},"Biomedical Research Centre","UNKNOWN",{"name":61,"class":59},"Oracle Cancer Trust","100414079","exploratory-study-of-clonal-evolution-in-cancer-for-patients-undergoing-transoral-robotic-surgery-for-radiation-exposed-residualrecurrent-tumours-of-the-upper-aerodigestive-tract-100414079",false,"NCT04671940","Exploratory Study of Clonal Evolution in Cancer for Patients Undergoing Transoral Robotic Surgery for Radiation Exposed Residual\u002FreCurrent Tumours of the Upper Aerodigestive Tract","RECUT PLUS: Exploratory Study of Clonal Evolution in Cancer for Patients Undergoing Transoral Robotic Surgery for Radiation Exposed Residual\u002FreCurrent Tumours of the Upper Aerodigestive Tract","RECUT Plus","Inclusion criteria\n\n* Aged over 18\n* Previous H\\&N cancer treated with radiotherapy.\n* Undergoing TORS as part of their management for residual, recurrent or new primary H\\&N cancer.\n\nExclusion criteria\n\n* Where TORS is used in a diagnostic setting only\n* Nasopharyngeal and thyroid head and neck cancers\n* Where no tissue specimens are available from the recurrent\u002Fresidual\u002Fsecondary tumour for the retrospective cohort","ALL","19 Years",{"count":73,"type":74},20,"ESTIMATED","OBSERVATIONAL","Radical radiotherapy for head and neck squamous cell cancer (HNSCC) can be administered to primary disease with curative intent. Residual disease, recurrence or further tumours may subsequently occur in this irradiated field. It is unknown whether these cancers reflect primary resistance or represent the evolution of resistance on treatment.\n\nUnderstanding this could allow stratification of patients to more effective primary treatments, such as transoral robotic surgery, or help tailor systemic therapies for these cancers in previously irradiated fields.\n\nRECUT+ is an exploratory molecular analysis study to assess the selective impact of radiation therapy on HNSCC.\n\nParticipants will be recruited from the Royal Marsden Hospital (RMH), Chelsea, a tertiary referral H\\&N cancer unit in London, UK, specialising in transoral robotic surgery.\n\nRetrospective participants will be identified from previous Head and neck MDT lists at RMH.\n\nProspective participants will be screened for by the RECUT+ team during the weekly H\\&N MDT meetings at the Royal Marsden Hospital (RMH).\n\nBlood\u002Fsaliva samples will be collected pre operatively (prospective participants) and post operatively (retrospective and prospective participants) for germline and circulating tumour DNA analysis.\n\nBiopsy samples from the original cancer and resected specimens from the post radiotherapy residual\u002Frecurrent\u002Fnew primary disease will undergo molecular analysis to assess for any selective impact of radiotherapy on these further tumours.",[78],"Head and Neck Cancer","2026-02-09",{"date":81,"type":82},"2026-02-12","ACTUAL",{"date":84,"type":82},"2020-11-18",{"date":86,"type":74},"2026-10-07",{"name":5,"class":6},1]